A Phase 1/2 Multicenter, Open Label, Dose Ranging Study of DN-101 and Taxotere® in Patients With Advanced (Stage IIIB or IV) Non-Small Cell Lung Cancer (NSCLC) Who Have Failed Previous Therapy With Platinum-Based Chemotherapy

Trial Information

A Phase 1/2 Multicenter, Open Label, Dose Ranging Study of DN-101 and Taxotere® in Patients With Advanced (Stage IIIB or IV) Non-Small Cell Lung Cancer (NSCLC) Who Have Failed Previous Therapy With Platinum-Based Chemotherapy

DN-101 is an oral anti-cancer therapy for solid tumors and various hematologic malignancies.
DN-101 is a unique formulation of calcitriol specifically designed for use in cancer.
Calcitriol is a naturally occurring hormone and the most potent biologically active form of
vitamin D. In high doses, calcitriol is active in many laboratory and animal models of
cancer and synergistic with many commonly used chemotherapeutic agents. Until recently, the
clinical use of calcitriol as an anti-cancer therapy was limited by hypercalcemia at doses
required for anti-tumor activity. Based upon clinical results to date, Novacea believes it
has successfully developed a solution to this problem through development of DN-101.

Chemotherapy for NSCLC, while not curative, has been shown to prolong survival in patients
with unresectable disease. A number of different chemotherapy agents have been shown to have
single-agent activity in NSCLC. These include cisplatin, carboplatin, vinorelbine,
gemcitabine, paclitaxel and docetaxel. For first-line therapy of Stage IIIB or Stage IV
NSCLC, these agents are generally used in combination. In most cases, first-line
chemotherapy consists of a platinum-based agent, either cisplatin or carboplatin, and
another chemotherapeutic.

Only one agent, Taxotere®, has been approved in the United States by the Food and Drug
Administration for use as second-line chemotherapy in NSCLC.